KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Raw Materials (2018 - 2026)

Twist Bioscience has reported Raw Materials over the past 9 years, most recently at $25.5 million for Q1 2026.

  • Quarterly Raw Materials rose 78.74% to $25.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.5 million through Mar 2026, up 78.74% year-over-year, with the annual reading at $20.2 million for FY2025, 16.6% up from the prior year.
  • Raw Materials was $25.5 million for Q1 2026 at Twist Bioscience, up from $24.7 million in the prior quarter.
  • Over five years, Raw Materials peaked at $33.6 million in Q1 2023 and troughed at $14.3 million in Q1 2025.
  • The 5-year median for Raw Materials is $24.7 million (2025), against an average of $24.7 million.
  • Year-over-year, Raw Materials soared 180.8% in 2022 and then plummeted 35.92% in 2024.
  • A 5-year view of Raw Materials shows it stood at $33.6 million in 2022, then decreased by 29.22% to $23.8 million in 2023, then crashed by 32.51% to $16.0 million in 2024, then soared by 53.86% to $24.7 million in 2025, then increased by 3.58% to $25.5 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Raw Materials are $25.5 million (Q1 2026), $24.7 million (Q4 2025), and $20.2 million (Q3 2025).